Clinicopathological significance of cell cycle regulation markers in a large series of genetically confirmed Ewing's Sarcoma Family of Tumors

• Published in: International journal of cancer Vol. 128; no. 5; pp. 1139 - 1150
• Main Authors: López‐Guerrero, José Antonio, Machado, Isidro, Scotlandi, Katia, Noguera, Rosa, Pellín, Antonio, Navarro, Samuel, Serra, Massimo, Calabuig‐Fariñas, Silvia, Picci, Piero, Llombart‐Bosch, Antonio
• Format: Journal Article
• Language: English
• Published: Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.03.2011; Wiley-Blackwell; Wiley Subscription Services, Inc
• Subjects: 9p21; Adolescent; Adult; Aged; Aged, 80 and over; Biological and medical sciences; Biomarkers, Tumor - metabolism; Cancer; Cell Cycle; Child; Child, Preschool; Chromosome 22; Chromosome Deletion; Chromosome rearrangements; Chromosomes, Human, Pair 22; Cohort Studies; Cyclin-dependent kinase inhibitor p21; Cyclin-dependent kinase inhibitor p27; Diseases of the osteoarticular system; ETS protein; Ewing Sarcoma Family of Tumors; Ewing's sarcoma; Ewings sarcoma; EWS protein; Female; Fluorescence in situ hybridization; Gene fusion; Genes, p53; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Infant; Ki67; Male; Medical prognosis; Medical research; Medical sciences; Middle Aged; p53; p53 Protein; Patients; Prognosis; Radiation therapy; RNA-Binding Protein EWS - genetics; Sarcoma, Ewing - genetics; Sarcoma, Ewing - pathology; Transcription factors; Tumors; Tumors of striated muscle and skeleton; Young Adult; Genetic mapping; Ewing sarcoma; Prognosis; Diseases of the osteoarticular system; Biological marker; Malignant tumor; 9p21; Chromosome C9; p53; Cancerology; TP53 Gene; Cell cycle; Ki67 antigen; Genetics; Ewing Sarcoma Family of Tumors; Ki67; Cancer; Tumor suppressor gene
• ISSN: 0020-7136; 1097-0215
• DOI: 10.1002/ijc.25424

More than 90% of all Ewing's Sarcoma Family of Tumors (ESFT) exhibit specific chromosomal rearrangements between the EWS gene on chromosome 22 and various members of the ETS gene family of transcription factors. The gene fusion type and other secondary genetic alterations, mainly involving cell cycle regulators, have been shown to be of prognostic relevance in ESFT. However, no conclusive results have been reported. We analyzed the clinicopathological significance of relevant cell cycle regulators in genetically confirmed ESFT. A total of 324 cases were analyzed for the immunohistochemical expression of p53, p21Waf1/Cip1, p27Kip1 and Ki67 and the chromosomal alterations of the p53 and 9p21 locus by fluorescent in situ hybridization. We observed that expression of p53 (p = 0.025), p21Waf1/Cip1 (p = 0.015) and p27Kip1 (p = 0.013) was higher in disseminated than in localized disease. Furthermore, a cohort of 217 patients with localized disease was considered for studying the prognosis involvement of these factors on patient follow‐up. The median follow‐up was 39 months (range: 0.17–452) with an overall survival (OS) of 55%. Ki67 was expressed in 34% of cases and constituted an independent prognostic factor for progression free survival and OS independently of the type of treatment [hazard ratio of 2.0 (95% CI: 1.3–3.1; p = 0.003) and 1.9 (95% IC: 1.3–2.9; p = 0.007) for progression free survival and OS, respectively, being especially relevant in the group of patients which incorporated radiotherapy in their regimen schedules. In conclusion, this study demonstrates that Ki67 expression constitutes a valuable indicator of poor prognosis in localized ESFT.